Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: J Infect Chemother. 2015 Mar 20;21(7):507–511. doi: 10.1016/j.jiac.2015.03.007

Table 4.

Vancomycin dosing and pharmacokinetic characteristics of obese vs non-obese patients (N=108)

Obese
(n=37)		 Non-Obese
(n=71)		 P-value
Vancomycin trough (mg/L), mean (SD) 16.5 (9.2) 12.1 (5.0) 0.004
Vancomycin trough < 15mg/L, n (%) 21 (56.8) 49 (69.0) 0.21
Vancomycin trough > 20 mg/L, n (%) 7 (18.9) 3 (4.2) 0.03
Vancomycin dose (mg/kg/day), mean (SD) 23.9 (7.3) 26.0 (8.7) 0.18
Estimated vancomycin pharmacokinetic parameters, mean (SD)
  CLVAN (L/hr) 4.7 (1.3) 4.4 (1.4) 0.34
  VD (L) 74.4 (14.5) 50.4 (9.3) < 0.001
  T1/2 (hr) 11.8 (3.7) 8.5 (2.5) < 0.001
Estimated half-lives elapsed prior to trough, mean (SD) 5.1 (2.1) 6.6 (2.8) < 0.001
Percent of steady state achieved, mean (SD) 94.6 (4.4) 97.5 (2.6) < 0.001